| rivaroxaban / Generic mfg. |
2020-001053-44: Stabilization of atherosclerosis in carotid artery by Rivaroxaban as evaluated by 3D ultrasound with contrast |
|
|
| Not yet recruiting | 4 | 62 | Europe | Film-coated tablet, Xarelto® | Rigshospitalet, Department of Vascular Surgery, Bayer AG | Patients with - Stable peripheral artery diseaseand- Asymptomatic, atherosclerotic plaque/stenosis in the carotid artery; asymptomatic regarding cerebral ischaemia including stroke and transient ischaemic attack (TIA) or amaurosis fugax. Patienter med - Stabil perifer arteriel sygdomog - Asymptomatisk, aterosklerotisk plaque/stenose in carotis; asymptomatisk vedr. iskæmisk apopleksi inkluderende stroke og transient cerebral iskæmi (TCI) eller amaurosis fugax., Patients with: - Atherosclerosis in limb arteries and - Atherosclerosis in carotid artery with no symptoms of major or minor stroke or temporary vision loss. Patienter med:- Åreforkalkning i underekstremitets blodkarog- Åreforkalkning i halspulsåren uden symptomer på slagtilfælde eller forbigående synstab., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
SPIRIT, NCT05797376: Effects of aSPIrin Versus Aspirin Plus Low-dose RIvaroxaban on Carotid aTherosclerotic Plaque Inflammation |
|
|
| Recruiting | 4 | 92 | RoW | Rivaroxaban 2.5mg, Xarelto 2.5mg | Asan Medical Center, Bayer | Atherosclerosis of Artery, Coronary Artery Disease, Peripheral Arterial Disease, Carotid Stenosis | 12/24 | 06/25 | | |
NCT04142125: Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease |
|
|
| Completed | 3 | 101 | Canada | Rivaroxaban 2.5 Mg Oral Tablet bid, Xarelto, Acetylsalicyclic acid 81 mg tablet qd, Aspirin | Population Health Research Institute | Ischemic Stroke, Intracranial Atherosclerotic Disease | 09/23 | 09/23 | | |
CAPTIVA, NCT05047172: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis |
|
|
| Recruiting | 3 | 1683 | US | Ticagrelor + Aspirin, Brilinta, Rivaroxaban + Aspirin, Xarelto, Clopidogrel + Aspirin, Plavix, Risk Factor Management | University of Florida, National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati, Medical University of South Carolina, Janssen Scientific Affairs, LLC, AstraZeneca | Intracranial Arteriosclerosis, Stroke | 05/27 | 05/27 | | |
AA-ICAS, NCT05700266: Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis |
|
|
| Not yet recruiting | 2/3 | 1180 | NA | Rivaroxaban, Clopidogrel, Aspirin, Risk Factor Management in both arms | The First Affiliated Hospital with Nanjing Medical University, National Natural Science Foundation of China | Ischemic Stroke, Intracranial Atherosclerosis, Stenosis | 12/24 | 12/24 | | |
PRO-PAS, NCT06239415: PAtients With Symptomatic Peripheral Artery Disease on Rivaroxaban-acetylsalicylic Acid Combination Therapy |
|
|
| Recruiting | N/A | 250 | Europe | observation | Istituti Clinici Scientifici Maugeri SpA, Società Italiana Cardiologia Ospedalità Accreditata (SICOA) | Peripheral Atherosclerotic Disease | 03/24 | 03/24 | | |
NCT04847752: Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis |
|
|
| Recruiting | N/A | 1000 | RoW | carotid artery stenting, CAS, carotid endarterectomy, CEA, Aspirin, ASP, Clopidogrel, plavix, Anticoagulant, warfarin, rivaroxaban, dabigatran, any other anticoagulant therapy, Statin, atorvastatin, rosuvastatin, any other statin drugs, PCSK9 inhibitor, Evolocumab, Alirocumab, any other PCSK9 inhibitors | Tongji Hospital | Ischemic Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis) | 12/26 | 12/28 | | |
